Premium
Retrospective Analysis of the Use of Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumor (GIST).
Author(s) -
Boulos Badi M.,
Jajeh Ahmad,
Nawaz Ubaid,
Osafo David,
Tamkus Drimante,
Ogundipe Olsuola,
Menini Perry,
Bamrolia Ansul
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1189
Subject(s) - gist , imatinib , medicine , imatinib mesylate , myeloid leukemia , tyrosine kinase inhibitor , stromal tumor , oncology , tyrosine kinase , gastroenterology , stromal cell , cancer , receptor
Imatinib is a relatively selective tyrosine kinase inhibitor with activity against all ABL‐tyrosiine kinase platlet derived growth factor, alpha and beta as well as C‐kit. It was approved by the FDA over the last 4 years. Fifty patients with CML and 17 patients with GIST’s were treated for 4 years with Imatinib. Majority of our patients are African Americans (40% in CML and 58% in GIST). Flurescent In Situ Hybridization (FISH) was done post therapy In peripheral blood and bone marrow from CML cases. CT Imaging and PET Scanning were used to evaluate response in GIST’s. Complete disappearance of BCR‐ABL by FISH was seen in 44% of patients with CML. Response for GIST’s was 70%. Resistance to Imatinib was 5% in GIST and 3% in CML with chronic and accelerated phase. The response rates in our studies compare similar to reported Phase III and Phase II studies in CML and GIST respectively. None of the patients developed congestive heart failure or cardiac myopathy.